ZYME
Zymeworks Inc. Health Care Pharmaceutical Preparations Russell 3000
$28.61Close
$2.1BMarket cap
$16.46 – $31.0552-week range
Nov 5, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 84 · stronger than 84% of stocks over 12 months
- Tight base near its pivot pullbacks 18% → 13%; 1.2% above its $28.26 pivot
Cautions
- Earnings shrinking EPS −2160% year on year
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
8%
1wk
up 1.4%
price change
1mo
up 8.0%
price change
12-month return
up 50%
market up 11% ·
its own up 37%
F-score
—
— Not assessed
Altman Z
12.71
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.0×
price / book
Earnings yield
down 4.4%
EBIT / enterprise value
Cheaper than
18%
of the market · expensive
Revenue growth
up 39%
year on year
EPS growth
down 2160%
latest quarter
Sales growth
down 91%
latest quarter · +1 pts
ROE
down 27%
return on equity
Free cash margin
down 33%
-$34.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
3.9%
$1.12 a day · 2×ATR $26.38
RS
84 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.8×
vs 50-day average
Up/down volume
0.88
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Contractions
2
18% → 13%
Pivot
$28.26
1.2% above
Volume dry-up
1.4×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 8.2% over the year, from 69m to 75m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 20260% vs market2 sessions after results
Financials
- Net -77%
- Free cash -33%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $39.0M | $26.7M | $412.5M | $76.0M | $76.3M | $106.0M |
| Operating income | -$187.5M | -$215.6M | $130.5M | -$138.1M | -$137.1M | -$92.5M |
| Net income | -$180.6M | -$211.8M | $124.3M | -$118.7M | -$122.7M | -$81.1M |
| Net margin | -464% | -794% | 30% | -156% | -161% | -77% |
| Earnings per share | -$3.58 | -$4.06 | $1.91 | -$1.72 | -$1.62 | -$1.08 |
| Free cash flow | -$155.7M | -$204.9M | $136.0M | -$120.8M | -$112.0M | -$34.5M |
| Free cash margin | -400% | -768% | 33% | -159% | -147% | -33% |
| Cash | $242.0M | $201.9M | $400.9M | $157.6M | $66.1M | $41.2M |
| Shareholders' equity | $409.9M | $249.1M | $493.0M | $464.8M | $338.8M | $268.5M |
| Shares outstanding | — | 46.63m | 63.06m | 70.12m | 68.96m | 74.64m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 5, 2025 | Annual ↗ | Dec 31, 2024 | 64d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Mar 6, 2024 | Annual ↗ | Dec 31, 2023 | 66d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 23, 2026 | Material agreement · Regulation FD ↗ |
| Sep 23, 2026 | Material agreement · Acquisition or disposal · New obligation · Regulation FD ↗ |
| Aug 25, 2026 | Regulation FD · Other events ↗ |
| Aug 6, 2026 | Results · Regulation FD ↗ |
| Jun 29, 2026 | Material agreement · Regulation FD ↗ |
| May 14, 2026 | Regulation FD · Other events ↗ |
| May 7, 2026 | Results · Regulation FD ↗ |
| Apr 1, 2026 | Director or officer change ↗ |
| Mar 2, 2026 | Results · Regulation FD ↗ |
| Mar 2, 2026 | Material agreement · New obligation · Regulation FD ↗ |
| Jan 12, 2026 | Results · Director or officer change · Other events ↗ |
| Dec 30, 2025 | Shareholder vote ↗ |